When hot air balloonists land, they choose the field, they bring the champagne, they build the relationship. The farmer helps unload after trust is established. Healthcare manufacturers need to own demand creation and stop expecting distribution partners to do strategic work they were never equipped for.
The Champagne Tradition
When hot air balloons were first invented in 18th century France, rural communities thought aliens had descended from the sky.
Farmers watched these massive, colourful objects float down into their fields and panicked. Some ran. Others grabbed weapons. The balloon pilots needed a way to signal they came in peace.
Their solution? Dangle champagne from the basket as they descended.
The message was clear: "We're not invaders. We bring gifts. We respect that this is your land."
It worked. The champagne built trust. Farmers helped pack away the balloon, hauled heavy equipment onto trailers, and became part of the ballooning community. Some fields became regular landing sites — trusted bases where balloonists could launch again and again.
The tradition still exists today. And it contains everything most healthcare manufacturers get wrong about market expansion.
The balloonists didn't hire a local guide and tell them "find us somewhere to land and let us know how it goes." They studied the wind patterns themselves. They chose the landing site. They brought the champagne. They built the relationship directly.
The local farmer helped with logistics, but only after trust was established.
Your market expansion should work the same way.
Why Market Expansion Keeps Failing: The Partner Dependency Trap
Here's what I've actually seen happen when healthcare manufacturers enter new markets.
You sign a distribution agreement with a partner who has "strong relationships" in Germany. You brief them on your product. You provide some marketing materials. You set revenue targets. Then you wait.
Three months later, you ask how it's going. "We're having conversations. Lots of interest. These things take time in this market."
Six months later, you ask for a pipeline review. "We've presented to several accounts. Very positive feedback. A few trials starting soon."
Nine months later, you ask about actual revenue. "The regulatory approval took longer than expected. And you know how cautious German procurement is. But we're optimistic about Q2."
Twelve months later, you've spent €150K supporting a partner who's generated €40K in revenue and has no sustainable pipeline.
You blame the market. You blame the partner. You consider switching distributors.
But the problem isn't the partner. The problem is you handed them responsibility for something they were never equipped to do: strategic market entry and demand creation.
What Your Partner Actually Does (vs. What You Need)
What you need for market expansion:
- Strategic identification of key opinion leaders who influence market adoption
- Sophisticated demand creation that builds awareness in target segments
- High-level relationship building with influential healthcare professionals
- VIP engagement strategies that position your innovation as category-defining
- Content and thought leadership that establishes clinical credibility
- Events and experiences that create peer advocacy and adoption momentum
What your partner actually does:
- Calls their existing contacts and asks if they want to evaluate your product
- Sends your brochure to procurement departments they've worked with before
- Attends local conferences with your booth materials and collects business cards
- Follows up on inbound enquiries when healthcare professionals contact them
- Provides local logistics, regulatory support, and order fulfilment
Your partner is built for distribution, not demand creation.
They're excellent at fulfilling orders, managing inventory, handling local regulatory requirements, and providing technical support. They know the market's procurement processes. They have established relationships with hospital administrators.
But they don't run sophisticated LinkedIn campaigns targeting interventional cardiologists. They don't create thought leadership content that positions your innovation as advancing clinical outcomes. They don't host VIP invitation events that make key opinion leaders feel strategically chosen.
And they're certainly not bringing champagne.
The Consequences of Outsourcing Market Entry
Consequence 1: Your partner sells to who they know, not who matters. Your partner has relationships with mid-tier hospitals they've worked with for years. Those relationships are built on reliable service and competitive pricing — not on introducing breakthrough innovations to influential early adopters. So they approach the accounts they're comfortable with. Not the key opinion leaders who will drive market adoption.
Consequence 2: Your innovation gets positioned as "another product option." Your partner doesn't understand how to position breakthrough innovation. They understand how to position product features against competitor specifications. So when they present your innovation, it sounds like: "Here's a new device with these technical advantages over existing options. Would you like to evaluate it?" Not: "Here's how leading institutions are solving this clinical challenge."
Consequence 3: You lose control of your brand narrative. Every conversation your partner has with prospects shapes how your innovation is perceived in that market. And you have no visibility into — much less control over — those interactions.
Consequence 4: Key opinion leaders never hear from you. The healthcare professionals who will drive adoption in this market aren't in your partner's contact list. They're strategic targets who need to be deliberately identified, researched, and approached with tailored value propositions.
Consequence 5: Your partner reports activity, not progress. Every quarterly review sounds the same: "We attended three conferences and collected 150 contacts. We're in discussions with 12 potential accounts." It sounds like progress. It's activity metrics.
The Modern Reality: You Can Control Market Entry
LinkedIn gives you direct access to key opinion leaders in any market. You don't need a partner's contact list. You can identify and reach interventional cardiologists in Munich, department heads in Paris, and innovative surgeons in Amsterdam without ever relying on distributor introductions.
Digital campaigns let you target precisely by speciality, institution, geography, and even specific accounts.
Content positions you before conversations happen. Educational videos, thought leadership articles, clinical insights shared on the right channels — you can establish credibility and start building relationships long before anyone picks up the phone.
Virtual and targeted in-person events create high-value engagement without requiring permanent local infrastructure.
The technology exists for brands to own demand creation and hand qualified leads to partners for conversion and support.
What Strategic Market Entry Actually Looks Like
Phase 1: Target Identification (Months 1–2). Map the top 50 influential healthcare professionals in your target speciality and geography. Identify the institutions where innovation gets adopted first. Research their clinical priorities, recent publications, and speaking topics. Your partner can provide input. But you own the targeting strategy.
Phase 2: Direct Engagement (Months 2–4). Run sophisticated demand creation that builds awareness and interest. LinkedIn campaigns targeting your identified VIPs with clinical insights, not product pitches. Educational content addressing the problems they're trying to solve. Case studies and outcomes data from existing markets that build credibility. You're not selling yet. You're building awareness.
Phase 3: VIP Invitation (Months 4–6). Host an exclusive event — virtual or in-person — designed specifically for the influential healthcare professionals you've identified. Not a product launch. Not a sales presentation. An invitation to be part of something significant. The event makes them feel chosen. Strategic. Part of an exclusive community advancing their field.
Phase 4: Qualified Handoff (Months 6+). Now, and only now, do partners take over. After the event, you've built direct relationships with key opinion leaders. You hand them to your partner with context: "Dr. Schmidt attended our Innovation Summit, completed hands-on training, expressed strong interest. He's expecting your follow-up to discuss logistics and procurement pathways."
Your partner now does what they're good at: navigating local procurement, handling regulatory requirements, managing implementation logistics, providing ongoing support.
The demand creation, the relationship building, the strategic positioning, the VIP engagement — you owned that.
The Honest Truth About Partners
This isn't anti-partner. Partners are essential for market expansion — in their proper role.
Good partners provide: local regulatory expertise and compliance navigation, established logistics and fulfilment infrastructure, technical support and service capabilities, procurement relationship management, and implementation and training execution.
What partners cannot provide — and were never designed to provide — is sophisticated demand creation that establishes your innovation with key market influencers.
Expecting your partner to identify, target, and engage the influential healthcare professionals who will drive adoption is like expecting the farmer to launch the hot air balloon.
That's not their job. It's yours.
The balloonists brought the champagne. The balloonists chose where to land. The balloonists built the relationship. Then the farmer helped with the logistics.
Stop waiting for partners to bring you leads. Start bringing them qualified opportunities they can convert.
What next?